Explore: The Journal of Science and Healing
Volume 4, Issue 4 , Pages 259-263 , July 2008

Complementary and Alternative Medicine Use Was Associated With Higher Perceived Physical and Mental Functioning in Early Systemic Sclerosis

  • Sonya E. Hunnicutt, MA, MS

      Affiliations

    • Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX
    • ,
  • James Grady, PhD

      Affiliations

    • Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX
    • ,
  • Terry A. McNearney, MD

      Affiliations

    • Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX
    • Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX
    • Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX
    • Corresponding Author InformationCorresponding Author. Address: 301 University Blvd, Galveston, TX 77555-1165

References 

  1. Denton CP, Black CM, Abraham DJ. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol. 2006;2:134–144
  2. Soeken KL. Selected CAM therapies for arthritis-related pain: the evidence from systematic reviews. Clin J Pain. 2004;20:13–18
  3. Breuer GS, Orbach H, Elkayam O, et al. Perceived efficacy among patients of various methods of complementary alternative medicine for rheumatologic diseases. Clin Exp Rheumatol. 2005;23:693–696
  4. Rao JK, Kroenke K, Mihaliak KA, Grambow SC, Weinberger M. Rheumatology patients' use of complementary therapies: results from a one-year longitudinal study. Arthritis Rheum. 2003;49:619–625
  5. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581–590
  6. Reveille JD, Fischbach M, McNearney T, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001;30:332–334
  7. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36).I. Conceptual framework and item selection. Med Care. 1992;30:473–483
  8. Stewart AL, Hays RD, Ware JE. The MOS short-form general health survey (Reliability and validity in a patient population). Med Care. 1988;26:724–735
  9. Brennan P, Silman A, Black C, et al. Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon (The UK Scleroderma Study Group). Br J Rheumatol. 1993;32:357–361
  10. Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol. 1993;20(11):1892–1896
  11. Medsger TA, Bombardieri S, Czirjak L, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003;21:S42–S46
  12. Del Rosso A, Boldrini M, Agostino D, et al. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum. 2004;51:475–481
  13. Danieli E, Paolo A, Lorenzo B, et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol. 2005;24:48–54
  14. Khanna D, Clements PJ, Furst DE, et al. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum. 2005;52:592–600
  15. Khanna D, Furst DE, Clements PJ, et al. Relaxin Study Group Scleroderma Clinical Trials Consortium (Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial). J Rheumatol. 2005;32:832–840
  16. Khanna D, Yan X, Tashkin DP, et al. Scleroderma Lung Study Group Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007;56:1676–1684

 Supported by National Institutes of Health (NIH) Specialized Center of Research Grant in Scleroderma P50AR44888, NIH Centers for Research Translation P50AR054144, and R21 AG023951 from the NIH National Institute on Aging. Studies were conducted at the General Clinical Research Center at the University of Texas Medical Branch at Galveston, funded by grant M01 RR 00073 from the National Center for Research Resources, NIH, United States Public Health Services.

PII: S1550-8307(08)00097-9

doi: 10.1016/j.explore.2008.04.004

Explore: The Journal of Science and Healing
Volume 4, Issue 4 , Pages 259-263 , July 2008

Article Tools

* Image Usage & Resolution